Clinical Trial Technology Editorial

  1. Has Fitbit Shown Us The Future Of Clinical Trials?
    9/4/2018

    David Pogue, a tech columnist for Yahoo Finance, notes Fitbit has collected 150 billion hours of heart-rate data from tens of millions of people all over the world. In January, Fitbit gave Pogue a deep dive into the data it collected. The finding may bode well for the use of activity trackers in future trials.

  2. Will AI Make Clinical Trials Faster & More Efficient?
    8/15/2018

    A new brief by CB Insights focuses on AI and its potential to transform clinical trials. A makeover of the $65 billion clinical trials market is well overdue. With all of the issues that seem to be preventing more efficient trials, will AI be the technology that finally streamlines the process?

  3. Adverse Event Reporting On Social Media — What You Need To Know
    7/17/2018

    Adverse events (a suspected reaction to the API or to the API in combination with prescribed medicines or environmental factors) are, naturally, a challenging situation for patients in a clinical trial and may, in rare cases, become severe or even fatal. For sponsors, contract research organizations (CROs), and logistics partners, early notification and accurate information is vital to understanding and responding to a suspected adverse event. What happens if the patient goes off protocol and turns to social media?

  4. How A Digital R&D Strategy Can Improve Clinical Trial Innovation And Execution
    6/26/2018

    The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials. This is the second of two articles that shares interview findings and insights published in the new Deloitte report, Digital R&D: Transforming the future of clinical development.

  5. DIA 2018 Will Focus On Two Major Trends
    6/12/2018

    Sudip Parikh, SVP & managing director, Americas at DIA Global, sees two trends that will continue to have a profound impact on potentially powerful new treatments and the clinical trials that make them possible. Both will be front and center at DIA’s 2018 Annual Meeting.

  6. Assessing The Value Of Wearables In Interventional Clinical Trials
    5/24/2018

    Advancements in biosensor technology are becoming increasingly common in the consumer space, with wrists adorned with Fitbits or similar devices, clothing embedded with “intelligent” fibers, and personal safety devices seen in healthcare facilities across the nation. Our culture is increasingly accustomed to tracking health metrics through smartphones and simple recreational wearables. In the pharmaceutical space, we are now seeing where success in the consumer segment can translate to value-adds for clinical trials.

  7. What Does Patient-Centricity Really Mean — And Why Do We Need It?
    5/22/2018

    The challenge to recruit and retain numbers of patients for Phase 3 industry-sponsored trials is not new to the industry. In fact, 48 percent of sites miss their enrollment targets and 80 percent of trials are delayed due to recruitment, but there are new opportunities to achieve recruitment goals while also minimizing dropout. 

  8. Digital R&D: 4 Ways To Maximize Patient Engagement In Clinical Trials
    5/15/2018

    The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials. This is the first of two articles that shares interview findings and insights published in the new Deloitte Center for Health Solutions report Digital R&D: Transforming the future of clinical development.

  9. Kazia Tries Adaptive Approach For Brain Cancer Trial
    5/14/2018

    Getting drugs to cross the blood-brain barrier can be a challenge for sponsor companies. Kazia Therapeutics is working on a treatment for glioblastoma, the most common and aggressive form of brain cancer. Kazia will use an adaptive approach in a Phase 2 trial using a product which was designed by Genentech to cross the blood-brain barrier.

  10. How Can Disruptive Trial Models Help Us Meet Patients In The Real World?
    5/3/2018

    When it comes to drug development, the pharmaceutical industry has long followed the same model for how we approach clinical trials. However, we are on the precipice of a new opportunity for the entire healthcare system in which emerging technologies can help us develop and deliver medicines to patients in more agile and efficient ways than ever before.